GWAS in Cancer Susceptibility and Therapeutic Target Discovery
Oriental Journal Of Chemistry · 31.10.2026 · 5 (42) · 2172
DOI: 10.13005/ojc/420533 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oriental Journal Of Chemistry, online erschienen am 30.10.2026. Verfasst von Alankar Shrivastav und 3 weiteren Autor:innen. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Genome-wide association studies (GWAS) have emerged as a revolution in the discovery of genetic determinants underlying cancer susceptibility by revealing germline variants that influence risk, progression and treatment response. In recent years, large-scale GWAS consortia have identified thousands of cancer loci in a wide variety of tumor types and importantly have shed light on inherited risk for cancer and functional elements within the noncoding genome as major contributors to oncogenic processes. These discoveries have widened the horizon of cancer genetics beyond high-penetrance mutations by establishing and recognizing for the first time ever, gaining importance of cumulative effect of common low-effect alleles and polygenic risk. In addition, the integration of GWAS data with transcriptomic, epigenomic and proteomic information has expedited functional interpretation of risk loci revealing pathways involved in DNA repair, immune modulation, cell proliferation and hormone signaling. Aside from vulnerability, GWAS-based findings have also been serving to shape medical strategies, by revealing druggable targets, biomarkers for treatment selection and risk stratification models. However, challenges including missing heritability, lack of population representation, gene-environment interactions and poor clinical translation remain. In this review, we discuss the current GWAS findings in several common cancers, recent methodological and analytical developments of GWAS studies that help improve our understanding of cancer biology, knowledge gained from GWAS findings for potential clinical application for therapy development, and address challenges encountered by these studies toward precision oncology.
Zitieren
APA
Shrivastav, A., Kumari, P., Devi, K., & Rastogi, A. (2026). GWAS in Cancer Susceptibility and Therapeutic Target Discovery. Oriental Journal Of Chemistry, 5(42), 2172. https://doi.org/10.13005/ojc/420533
Vancouver
Shrivastav A, Kumari P, Devi K, Rastogi A. GWAS in Cancer Susceptibility and Therapeutic Target Discovery. Oriental Journal Of Chemistry. 2026;5(42):2172. doi:10.13005/ojc/420533
BibTeX
@article{Shrivastav2026,
author = {Shrivastav, Alankar and Kumari, Preeti and Devi, Kajal and Rastogi, Apoorv},
title = {GWAS in Cancer Susceptibility and Therapeutic Target Discovery},
journal = {Oriental Journal Of Chemistry},
year = {2026},
volume = {5},
number = {42},
pages = {2172},
doi = {10.13005/ojc/420533}
}
EUVIMED